High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2025
Association Between Elevated Lipoprotein(a) and Diastolic Dysfunction: A Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sheashaa Hesham, Awad Kamal, Mohammed Arshad, Farina Juan M, Abbas Mohammed Tiseer, Pietri Milagros Pereyra, Scalia Isabel G, Ali Nima Baba, Bismee Nadera N, Esfahani Sogol Attaripour, Ibrahim Omar, Abdelfattah Fatmaelzahraa, Mahmoud Ahmed K, Lester Steven J, Simper David, Ayoub Chadi, Arsanjani Reza
Аннотация
INTRODUCTION: Lipoprotein(a) [Lp(a)] has been linked to myocardial fibrosis and endothelial dysfunction, proposed mechanisms for diastolic dysfunction (DD). This study assessed the association between elevated Lp(a) (≥ 50 mg/dL) and DD in patients with preserved ejection fraction (EF).
AIM: We analyzed 1492 adults (median age59) with an Lp(a) measurement and echocardiogram (1997-2024).
METHODS: Diastolicdysfunction required ≥ 3 abnormal echo parameters, as per recent guidelines. Logisticregression adjusting for potential confounders was performed.
RESULTS: Seventy-sevenpatients (5.1%) had DD. Lp(a) ≥ 50 mg/dL was not associated with DD [adjusted oddsratio (aOR): 0.89, 95% confidence interval (CI): 0.49-1.54]. However, age (aOR:1.03, p = 0.026), hypertension (aOR: 1.83, p = 0.042), diabetes mellitus (aOR: 2.43, p =0.002), and cardiovascular (CV) diseases (aOR: 1.90, p = 0.043) were associated withDD, while statin therapy was associated with reduced risk (aOR: 0.51, p = 0.016).
CONCLUSIONS: In the setting of preserved EF, Lp(a) was not associated with DD,emphasizing management of traditional CV risks.
AIM: We analyzed 1492 adults (median age59) with an Lp(a) measurement and echocardiogram (1997-2024).
METHODS: Diastolicdysfunction required ≥ 3 abnormal echo parameters, as per recent guidelines. Logisticregression adjusting for potential confounders was performed.
RESULTS: Seventy-sevenpatients (5.1%) had DD. Lp(a) ≥ 50 mg/dL was not associated with DD [adjusted oddsratio (aOR): 0.89, 95% confidence interval (CI): 0.49-1.54]. However, age (aOR:1.03, p = 0.026), hypertension (aOR: 1.83, p = 0.042), diabetes mellitus (aOR: 2.43, p =0.002), and cardiovascular (CV) diseases (aOR: 1.90, p = 0.043) were associated withDD, while statin therapy was associated with reduced risk (aOR: 0.51, p = 0.016).
CONCLUSIONS: In the setting of preserved EF, Lp(a) was not associated with DD,emphasizing management of traditional CV risks.